{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:06:46Z","timestamp":1788336406180,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00259-019-04611-1","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T01:02:36Z","timestamp":1574384556000},"page":"860-869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET\/CT"],"prefix":"10.1007","volume":"47","author":[{"given":"Divya","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Prasad","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-5584","authenticated-orcid":false,"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"issue":"10","key":"4611_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"key":"4611_CR2","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/"},{"key":"4611_CR3","unstructured":"Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System (4th Edition). International Agency for Research on Cancer (IARC); 2010; France, 13\u201314."},{"key":"4611_CR4","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1007\/s00330-011-2199-y","volume":"21","author":"R Kumar","year":"2011","unstructured":"Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011;21:2408\u201314.","journal-title":"Eur Radiol"},{"issue":"2","key":"4611_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0972-3919.130320","volume":"29","author":"TK Jain","year":"2014","unstructured":"Jain TK, Karunanithi S, Dhull VS, Roy SG, Kumar R. Carcinoma of unknown primary of neuroendocrine origin: accurate detection of primary with (68)Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI3-octreotide positron emission tomography\/computed tomography enterography. Indian J Nucl Med. 2014;29(2):122\u20133.","journal-title":"Indian J Nucl Med"},{"key":"4611_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105:295\u2013309.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"4611_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-DOTATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"4611_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1053\/j.semnuclmed.2016.04.003","volume":"46","author":"P Spang","year":"2016","unstructured":"Spang P, Herrmann C, Roesch F. Bifunctional gallium-68 chelators: past, present, and future. Semin Nucl Med. 2016;46(5):373\u201394.","journal-title":"Semin Nucl Med"},{"issue":"6","key":"4611_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1039\/C2CC37544C","volume":"49","author":"BP Waldron","year":"2013","unstructured":"Waldron BP, Parker D, Burchardt C, Yufit DS, Zimny M, Roesch F, et al. Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. Chem Commun (Camb). 2013;49(6):579\u201381.","journal-title":"Chem Commun (Camb)"},{"key":"4611_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.apradiso.2015.01.023","volume":"98","author":"J Seemann","year":"2015","unstructured":"Seemann J, Eppard E, Waldron BP, Ross TL, Roesch F. Cation exchange-based post-processing of 68Ga-eluate: a comparison of three solvent systems for labelling of DOTATOC, NO2AP(BP) and DATA(m). Appl Radiat Isot. 2015;98:54\u20139.","journal-title":"Appl Radiat Isot"},{"issue":"43","key":"4611_CR11","doi-asserted-by":"publisher","first-page":"10358","DOI":"10.1002\/chem.201701508","volume":"23","author":"E Farkas","year":"2017","unstructured":"Farkas E, Nagel J, Waldron BP, Parker D, T\u00f3th I, Br\u00fccher E, et al. Equilibrium, kinetic and structural properties of gallium(III) and some divalent metal complexes formed with the new DATAm and DATA5m ligands. Chem Eur J. 2017;23(43):10358\u201371.","journal-title":"Chem Eur J"},{"issue":"1","key":"4611_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13550-019-0516-7","volume":"9","author":"J-P Sinnes","year":"2019","unstructured":"Sinnes J-P, Nagel J, Waldron B, Maina T, Nock BA, Bergmann RK, et al. Instant kit-preparation of 68Ga-radiopharmaceuticals via the chimeric chelator DATA: proof-of-principle with [68Ga]Ga-DATA-TOC. EJNMMI Res. 2019;9(1):48.","journal-title":"EJNMMI Res"},{"key":"4611_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/cmdc.201500092","volume":"10","author":"J Seemann","year":"2015","unstructured":"Seemann J, Waldron BP, Roesch F, Parker D. Approaching \u2018kit-type\u2019 labelling with 68Ga: the DATA chelators. ChemMedChem. 2015;10:1019\u201326.","journal-title":"ChemMedChem"},{"key":"4611_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-016-0007-3","volume":"1","author":"J Seemann","year":"2016","unstructured":"Seemann J, Waldron BP, Parker D, Roesch F. DATATOC: a novel conjugate for kit-type 68Ga labelling of TOC at ambient temperature. EJNMMI Radiopharmacy Chem. 2016;1:4.","journal-title":"EJNMMI Radiopharmacy Chem"},{"key":"4611_CR15","doi-asserted-by":"publisher","first-page":"14584","DOI":"10.1039\/C7DT01684K","volume":"46","author":"AB Nock","year":"2017","unstructured":"Nock AB, Kaloudi A, Nagel J, Sinnes JP, Roesch F, Theodosia MT. Novel bifunctional DATA chelator for quick access to site-directed PET 68Ga-radiotracers: preclinical proof-of-principle with [Tyr3] octreotide. Dalton Trans. 2017;46:14584\u201390.","journal-title":"Dalton Trans"},{"key":"4611_CR16","first-page":"61","volume":"54","author":"V Prasad","year":"2010","unstructured":"Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54:61\u20137.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"4611_CR17","first-page":"119","volume":"44","author":"B Schmidt-Kreppel","year":"2017","unstructured":"Schmidt-Kreppel B, Plum T, Gaertner FC, Maina T, Nock BA, Bergmann RK, et al. Biodistribution of [68Ga]Ga-DATA-TOC in comparison with [68Ga]Ga-DOTATOC in normal tissues and neuroendocrine tumour lesions. Eur J Nucl Med Mol Imaging. 2017;44(2):119\u2013956.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"4611_CR18","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kj\u00e6r A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259\u201377.","journal-title":"Future Oncol"},{"issue":"11","key":"4611_CR19","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","volume":"58","author":"L Bodei","year":"2017","unstructured":"Bodei L, Ambrosini V, Herrmann K, Modlin I, et al. Current concepts in 68GA-DOTATATE NEN imaging: interpretation, biodistribution, dosimetry and molecular strategies. J Nucl Med. 2017;58(11):1718\u201326.","journal-title":"J Nucl Med"},{"issue":"2","key":"4611_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejrad.2010.07.022","volume":"80","author":"V Ambrosini","year":"2011","unstructured":"Ambrosini V, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S. PET\/CT with 68Gallium-DOTA-peptides in NET: an overview. Eur J Radiol. 2011;80(2):116\u20139.","journal-title":"Eur J Radiol"},{"issue":"3","key":"4611_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of [68Ga]Ga-DOTA-NOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364\u201372.","journal-title":"J Nucl Med"},{"issue":"1","key":"4611_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","volume":"42","author":"G Treglia","year":"2012","unstructured":"Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42(1):80\u20137.","journal-title":"Endocrine"},{"key":"4611_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00259-012-2123-y","volume":"39","author":"L Kabasakal","year":"2012","unstructured":"Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET\/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4611_CR24","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u201370.","journal-title":"J Nucl Med"},{"key":"4611_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0284185113496679","volume":"55","author":"J Yang","year":"2010","unstructured":"Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2010;55:389\u201398.","journal-title":"Acta Radiol"},{"key":"4611_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/j.semnuclmed.2011.02.001","volume":"41","author":"WA Breeman","year":"2011","unstructured":"Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314\u201321.","journal-title":"Semin Nucl Med"},{"key":"4611_CR27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","volume":"252","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850\u20136.","journal-title":"Ann Surg"},{"key":"4611_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.109.071712","volume":"51","author":"V Ambrosini","year":"2010","unstructured":"Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. [68Ga]Ga-DOTA-NOCPET\/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669\u201373.","journal-title":"J Nucl Med"},{"key":"4611_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2214\/AJR.11.7298","volume":"197","author":"N Naswa","year":"2011","unstructured":"Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET\/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol. 2011;197:1221\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"4611_CR30","first-page":"497","volume":"54","author":"B Waldron","year":"2013","unstructured":"Waldron B, Roesch F, Parker D. Novel chelators for 68-Gallium PET. J Nucl Med. 2013;54(2):497\u2013507.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04611-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:35:57Z","timestamp":1605918957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04611-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4611"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04611-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Received from Institute Ethics Committee (Ref. No. IECPG-101\/30.12.2015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical clearance"}},{"value":"Informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This work has not been submitted elsewhere or has not under consideration to any other journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}